02/07/2025
🧠How should neurologists approach conversations about novel or off-label therapies? The AAN’s new position statement, led by Dr. Larry B. Goldstein of the , offers a framework grounded in evidence, ethics, and informed consent. It emphasizes the importance of clinical trials, shared decision-making, and transparency about risks and benefits. A must-read for clinicians and policy advocates.
https://hubs.la/Q03vhKnC0
